

ABSTRACT OF THE DISCLOSURE

Methods for screening for agents capable of modulating human neuromedin U receptor 2 (NMUR2) activity are provided, as well as therapeutic methods for treating NMUR2-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting NMUR2-mediated pain or nociception.